Kostas Biliouris

Q: How accurate are Kostas Biliouris's stock ratings?

About 48% of Kostas's ratings were profitable over a one-year hold, with an average return of +6.7% per rating, measured by 13Foresight from historical prices.

Q: How is Kostas ranked?

Kostas Biliouris is ranked #1956 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Oppenheimer

Wall Street Analyst

★★★☆☆

#1956

on 13Foresight · ranked by our own returns

44%

Success Rate

+6.6%

Average Return

24 of 54 calls profitable · +41.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 44% of Kostas Biliouris's ratings turned a profit when each position was held for 1 year — averaging +6.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

67 Buy 3 Hold 0 Sell

Kostas's Stock Coverage 29 ratings · 2026-11-12

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
DYN Dyne Therapeutics	Oct 28, 2026	HOLD	Strong Buy +116.3% avg upside 31 analysts	$15.00 10.18% Downside	+2.6%	·
KRRO Korro Bio	Oct 28, 2026	BUY	Strong Buy +90.0% avg upside 19 analysts	$22.00 53.59% Upside	+13.5%	·
NRIX Nurix Therapeutics	Oct 13, 2026	BUY	Strong Buy +22.5% avg upside 28 analysts	$32.00 19.47% Upside	-26.2%	·
PEPG PepGen Inc.	Oct 07, 2026	BUY	Strong Buy +349.9% avg upside 9 analysts	$15.00 535.64% Upside	+115.0%	·
PRME Prime Medicine, Inc.	Sep 25, 2026	BUY	Strong Buy +101.6% avg upside 18 analysts	$11.00 133.03% Upside	+39.0%	·
IRD Opus Genetics	Sep 09, 2026	BUY	Strong Buy +231.4% avg upside 25 analysts	$20.00 444.99% Upside	-27.1%	·
EVMN Evommune, Inc.	Sep 09, 2026	BUY	Strong Buy +283.4% avg upside 13 analysts	$26.00 286.32% Upside	-25.7%	·
TRDA Entrada Therapeutics Inc	Sep 03, 2026	BUY	Strong Buy +370.4% avg upside 10 analysts	$23.00 407.11% Upside	-31.8%	·
PRQR ProQR	Aug 14, 2026	BUY	Strong Buy +683.4% avg upside 19 analysts	$9.00 547.49% Upside	-31.8%	·
OVID Ovid Therapeutics	Aug 14, 2026	BUY	Strong Buy +103.8% avg upside 19 analysts	$9.00 254.31% Upside	-9.2%	·
TSE:MSCL Satellos Bioscience	Aug 14, 2026	BUY	Strong Buy +223.2% avg upside 9 analysts	$55.86 485.45% Upside	-24.4%	·
LEGN Legend Biotech	Aug 12, 2026	HOLD	Strong Buy +182.3% avg upside 27 analysts	$40.00 84.89% Upside	-9.8%	·
SRPT Sarepta Therapeutics	Aug 06, 2026	BUY	Buy +223.8% avg upside 50 analysts	$35.00 88.07% Upside	+6.2%	·
ALNY Alnylam Pharma	Jul 31, 2026	BUY	Strong Buy +76.3% avg upside 53 analysts	$350.00 112.21% Upside	-22.3%	·
DSGN Design Therapeutics	Jun 15, 2026	BUY	Strong Buy +66.1% avg upside 9 analysts	$21.00 96.65% Upside	-8.3%	·
DTIL Precision BioSciences	Jun 09, 2026	BUY	Strong Buy +234.8% avg upside 12 analysts	$20.00 183.24% Upside	+54.5%	·
MGX Metagenomi, Inc.	Sep 25, 2025	HOLD	Strong Buy +1032.0% avg upside 8 analysts	—	-50.0%	·
FDMT 4D Molecular Therapeutics	Sep 25, 2025	HOLD	Strong Buy +185.0% avg upside 17 analysts	—	+71.9%	·
SLN Silence Therapeutics	Sep 25, 2025	HOLD	Buy +22.8% avg upside 11 analysts	—	+123.6%	·
JSPR Jasper Therapeutics	Sep 25, 2025	HOLD	Strong Buy +5062.9% avg upside 18 analysts	—	·	·
BEAM Beam Therapeutics	Sep 25, 2025	HOLD	Strong Buy +91.1% avg upside 25 analysts	—	+5.1%	·
BBIO BridgeBio Pharma	Sep 25, 2025	HOLD	Strong Buy +26.0% avg upside 36 analysts	—	+33.8%	·
NTLA Intellia Therapeutics	Sep 25, 2025	HOLD	Buy +187.2% avg upside 39 analysts	—	-29.3%	·
RCKT Rocket Pharmaceuticals	Sep 25, 2025	HOLD	Buy +546.4% avg upside 30 analysts	—	-18.6%	·
IONS Ionis Pharmaceuticals	Sep 25, 2025	HOLD	Strong Buy +74.1% avg upside 44 analysts	—	-29.3%	·
BMRN BioMarin Pharmaceutical	Sep 25, 2025	HOLD	Strong Buy +63.6% avg upside 52 analysts	—	+14.5%	·
CRSP Crispr Therapeutics AG	Sep 23, 2025	BUY	Buy +45.6% avg upside 41 analysts	$75.00 45.93% Upside	-8.2%	·
LENZ LENZ Therapeutics	Jan 29, 2024	HOLD	Buy +470.0% avg upside 17 analysts	—	+159.7%	·
LGND Ligand Pharma	Jun 16, 2022	BUY	Strong Buy -11.1% avg upside 16 analysts	$77.00 76.20% Downside	+64.8%	·

🔒 24 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Kostas Biliouris — Frequently Asked Questions

How accurate are Kostas Biliouris's stock ratings?

Based on the calls 13Foresight could measure, about 48% of Kostas's ratings were profitable over a one-year hold, with an average return of +6.7% per rating, or +0.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Kostas ranked on 13Foresight?

Kostas Biliouris is currently ranked #1956 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Kostas cover?

Kostas most recently has ratings on DYN, KRRO, NRIX, PEPG, PRME, IRD, EVMN, TRDA, PRQR, OVID, TSE:MSCL, LEGN and 17 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Kostas Biliouris

Rating Distribution

Welcome to 13Foresight!